Research Analysts Set Expectations for INTS Q1 Earnings

Intensity Therapeutics Inc. (NASDAQ:INTS) – Analysts at HC Wainwright issued their Q1 2027 EPS estimates for shares of Intensity Therapeutics in a research note issued on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth expects that the company will earn ($0.21) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Intensity Therapeutics’ current full-year earnings is ($3.41) per share. HC Wainwright also issued estimates for Intensity Therapeutics’ Q2 2027 earnings at ($0.22) EPS, Q3 2027 earnings at ($0.22) EPS and Q4 2027 earnings at ($0.26) EPS.

Several other research analysts have also issued reports on INTS. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a research note on Tuesday, July 21st. Citigroup reaffirmed a “buy” rating on shares of Intensity Therapeutics in a research note on Tuesday, August 11th. Finally, Benchmark reissued a “speculative buy” rating on shares of Intensity Therapeutics in a research note on Wednesday, May 20th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $22.25.

Intensity Therapeutics Price Performance

Intensity Therapeutics stock opened at $4.21 on Wednesday. The business’s 50-day simple moving average is $4.27 and its 200 day simple moving average is $5.44. The stock has a market cap of $13.72 million, a price-to-earnings ratio of -1.18 and a beta of 2.76. Intensity Therapeutics has a 12-month low of $3.51 and a 12-month high of $43.50. The company has a quick ratio of 5.00, a current ratio of 5.00 and a debt-to-equity ratio of 0.01.

Intensity Therapeutics (NASDAQ:INTS) last posted its earnings results on Tuesday, August 11th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24).

Hedge Funds Weigh In On Intensity Therapeutics

Institutional investors have recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in Intensity Therapeutics by 77.8% during the 4th quarter. Geode Capital Management LLC now owns 460,248 shares of the company’s stock worth $189,000 after buying an additional 201,357 shares during the period. Corient Private Wealth LLC bought a new position in Intensity Therapeutics during the 4th quarter worth about $41,000. State Street Corp lifted its holdings in shares of Intensity Therapeutics by 839.3% in the fourth quarter. State Street Corp now owns 136,200 shares of the company’s stock valued at $56,000 after purchasing an additional 121,700 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Intensity Therapeutics during the fourth quarter worth about $26,000. Finally, Mesirow Financial Investment Management Inc. lifted its stake in Intensity Therapeutics by 25.5% in the 4th quarter. Mesirow Financial Investment Management Inc. now owns 251,000 shares of the company’s stock valued at $103,000 after acquiring an additional 51,000 shares in the last quarter. Institutional investors own 3.74% of the company’s stock.

Key Stories Impacting Intensity Therapeutics

Here are the key news stories impacting Intensity Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its price target on Intensity Therapeutics to $7.00 from $5.00 and maintained a Buy rating. The new target represents substantial potential upside from the stock’s reference price of $4.21, likely supporting investor interest. Intensity Therapeutics price target raised by HC Wainwright
• Positive Sentiment: HC Wainwright forecast quarterly 2027 losses of $0.21 to $0.26 per share and reiterated its Buy rating. Although the company is expected to remain unprofitable, the firm’s coverage indicates a favorable long-term view of Intensity Therapeutics’ prospects.
• Neutral Sentiment: HC Wainwright’s estimates imply ongoing operating losses through 2027, including projected full-year losses of $3.41 per share based on the current consensus. These forecasts do not represent a change to the company’s actual results.
• Negative Sentiment: Brookline Capital Markets reduced its 2026 and 2027 EPS forecasts, including lowering its FY2026 estimate to a $3.41 loss per share from a $2.70 loss and its FY2027 estimate to a $2.41 loss from a $1.90 loss. It also cut its Q3 and Q4 2026 forecasts to losses of $0.77 and $0.71 per share, respectively.
• Negative Sentiment: Brookline also lowered its FY2028 forecast to a $6.01 loss per share from a $5.12 loss, suggesting expectations for elevated expenses and continued cash needs. It modestly raised its highly speculative FY2030 forecast to $13.27 per share from $12.72, but the near- and medium-term estimate reductions are more immediately relevant to valuation.

About Intensity Therapeutics

Intensity Therapeutics, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer.